European lipodystrophy registry: background and structure
Authors
Adams, Claire
Akinci, Baris
Ceccarini, Giovanni
D’Apice, Maria Rosaria
Gambineri, Alessandra
Hennekam, Raoul C. M.
Jeru, Isabelle
Lattanzi, Giovanna
Miehle, Konstanze
Nagel, Gabriele
Novelli, Giuseppe
Santini, Ferruccio
Santos Silva, Ermelinda
Savage, David B.
Sbraccia, Paolo
Schaaf, Jannik
Sorkina, Ekaterina
Tanteles, George
Vantyghem, Marie-Christine
Vatier, Camille
Vigouroux, Corinne
Vorona, Elena
Araújo-Vilar, David
Wabitsch, Martin
Publication Date
2020-01-15Journal Title
Orphanet Journal of Rare Diseases
Publisher
BioMed Central
Volume
15
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
von Schnurbein, J., Adams, C., Akinci, B., Ceccarini, G., D’Apice, M. R., Gambineri, A., Hennekam, R. C. M., et al. (2020). European lipodystrophy registry: background and structure. Orphanet Journal of Rare Diseases, 15 (1) https://doi.org/10.1186/s13023-020-1295-y
Abstract
Abstract: Background: Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state. Because of the rarity of each lipodystrophy subform, research in this area is difficult and international co-operation mandatory. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for patients with lipodystrophy. Results: The registry was build using the information technology Open Source Registry System for Rare Diseases in the EU (OSSE), an open-source software and toolbox. Lipodystrophy specific data forms were developed based on current knowledge of typical signs and symptoms of lipodystrophy. The platform complies with the new General Data Protection Regulation (EU) 2016/679 by ensuring patient pseudonymization, informational separation of powers, secure data storage and security of communication, user authentication, person specific access to data, and recording of access granted to any data. Inclusion criteria are all patients with any form of lipodystrophy (with the exception of HIV-associated lipodystrophy). So far 246 patients from nine centres (Amsterdam, Bologna, Izmir, Leipzig, Münster, Moscow, Pisa, Santiago de Compostela, Ulm) have been recruited. With the help from the six centres on the brink of recruitment (Cambridge, Lille, Nicosia, Paris, Porto, Rome) this number is expected to double within the next one or 2 years. Conclusions: A European registry for all patients with lipodystrophy will provide a platform for improved research in the area of lipodystrophy. All physicians from Europe and neighbouring countries caring for patients with lipodystrophy are invited to participate in the ECLip Registry. Study registration: ClinicalTrials.gov (NCT03553420). Registered 14 March 2018, retrospectively registered.
Keywords
Research, Rare endocrinological diseases, Lipodystrophy, Registry, Rare diseases, Adipose tissue
Sponsorship
Russian Science Foundation (17-75-30035)
French Ministry of Solidarity and Health, Assistance-Publique Hopitaux de Paris, Sorbonne Universite, Inserm and CardioMetabolism and Nutrition University Hospital Institute, France (ANR-10-IAHU)
French Ministry of Solidarity and Health, Assitance-Publique Hopiteaux de Paris, Sorbonne Université, Inserm and CardioMetabolism and Nutrition University Hospital Institute France (ANR-10-IAHU)
Wellcome Trust (WT 107064)
MRC Metabolic Disease Unit (MRC-MC-UU_12012/2)
Instituto de Salud Carlos III and the European Regional Development Fund (PI18/01890)
Conselleria de Industria, Xunta de Galicia (ED341b 2017/19)
Fundación Mutua Madrilena (Call 2015)
UCIBIO (UID/MULTI/04378/2019)
Identifiers
s13023-020-1295-y, 1295
External DOI: https://doi.org/10.1186/s13023-020-1295-y
This record's URL: https://www.repository.cam.ac.uk/handle/1810/316188
Rights
Attribution 4.0 International (CC BY 4.0)
Licence URL: https://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.